Suppr超能文献

报告的 NSAID“过敏”对背痛阿片类药物使用障碍的影响。

Impact of reported NSAID "allergies" on opioid use disorder in back pain.

机构信息

Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.

Division of General Internal Medicine, Massachusetts General Hospital, Boston, Mass.

出版信息

J Allergy Clin Immunol. 2021 Apr;147(4):1413-1419. doi: 10.1016/j.jaci.2020.08.025. Epub 2020 Sep 9.

Abstract

BACKGROUND

It is crucial to identify patients at highest risk for opioid use disorder (OUD) and to address challenges in reducing opioid use. Reported nonsteroidal anti-inflammatory drug (NSAID) allergies may predispose to use of stronger pain medications and potentially to OUD.

OBJECTIVE

We sought to investigate the clinical impact of reported NSAID allergy on OUD in patients with chronic back pain.

METHODS

We conducted a retrospective study of adults receiving care at a tertiary health care system from January 1, 2013, to December 31, 2018. Back pain and OUD were identified using administrative data algorithms. We used propensity score matching and logistic regression to estimate the impact of self-reported NSAID adverse drug reactions (ADRs) on risk of OUD, adjusting for other relevant clinical information.

RESULTS

Of 47,114 patients with chronic back pain, 3,620 (7.7%) had a reported NSAID ADR. In an adjusted propensity score-matched analysis, patients with NSAID ADRs had higher odds (odds ratio, 1.34; 95% CI, 1.07-1.67) of developing OUD as compared with those without NSAID ADRs. Additional risk factors for OUD included younger age, male sex, Medicaid insurance, Medicare insurance, higher number of inpatient and outpatient visits in the previous year, and comorbid anxiety and depression. Patients with listed NSAID ADRs also had higher odds of a documented opioid prescription during the study period (odds ratio, 1.22; 95% CI, 1.11-1.34).

CONCLUSIONS

Adults with chronic back pain and reported NSAID ADRs are at a higher risk of developing OUD and receiving opioid analgesics, even after accounting for comorbidities and health care utilization. Allergy evaluation is critical for potential delabeling of patients with reported NSAID allergies and chronic pain.

摘要

背景

识别阿片类药物使用障碍(OUD)风险最高的患者并解决减少阿片类药物使用的挑战至关重要。据报道的非甾体抗炎药(NSAID)过敏可能会导致更强的止痛药使用,并可能导致 OUD。

目的

我们旨在研究患有慢性背痛的患者报告的 NSAID 过敏对 OUD 的临床影响。

方法

我们对 2013 年 1 月 1 日至 2018 年 12 月 31 日期间在三级医疗保健系统接受治疗的成年人进行了回顾性研究。使用管理数据算法确定背痛和 OUD。我们使用倾向评分匹配和逻辑回归来估计自我报告的 NSAID 药物不良反应(ADR)对 OUD 风险的影响,同时调整其他相关临床信息。

结果

在 47114 例患有慢性背痛的患者中,有 3620 例(7.7%)报告了 NSAID ADR。在调整后的倾向评分匹配分析中,与没有 NSAID ADR 的患者相比,有 NSAID ADR 的患者发生 OUD 的几率更高(优势比,1.34;95%CI,1.07-1.67)。OUD 的其他危险因素包括年龄较小、男性、医疗补助保险、医疗保险、前一年的住院和门诊就诊次数较多,以及并发焦虑和抑郁。在研究期间,有 NSAID ADR 记录的患者也更有可能获得阿片类药物处方(优势比,1.22;95%CI,1.11-1.34)。

结论

患有慢性背痛和报告的 NSAID ADR 的成年人发生 OUD 和接受阿片类镇痛药治疗的风险更高,即使考虑到合并症和医疗保健利用情况也是如此。对于报告有 NSAID 过敏和慢性疼痛的患者,过敏评估对于潜在的重新标记至关重要。

相似文献

1
Impact of reported NSAID "allergies" on opioid use disorder in back pain.
J Allergy Clin Immunol. 2021 Apr;147(4):1413-1419. doi: 10.1016/j.jaci.2020.08.025. Epub 2020 Sep 9.
2
Nonsteroidal anti-inflammatory drug "allergy" labeling is associated with increased postpartum opioid utilization.
J Allergy Clin Immunol. 2024 Mar;153(3):772-779.e4. doi: 10.1016/j.jaci.2023.11.025. Epub 2023 Nov 30.
3
Association of Reported Nonsteroidal Anti-Inflammatory Drug (NSAID) Adverse Drug Reactions With Opioid Prescribing After Total Joint Arthroplasty.
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1891-1898.e3. doi: 10.1016/j.jaip.2023.03.017. Epub 2023 Mar 21.
4
Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System.
J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):737-743.e3. doi: 10.1016/j.jaip.2016.12.006. Epub 2017 Jan 18.
6
Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain.
Drug Alcohol Depend. 2020 Apr 1;209:107901. doi: 10.1016/j.drugalcdep.2020.107901. Epub 2020 Feb 14.
7
Neighborhood Socioeconomic Status and Receipt of Opioid Medication for New Back Pain Diagnosis.
J Am Board Fam Med. 2017 Nov-Dec;30(6):775-783. doi: 10.3122/jabfm.2017.06.170061.
9
Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
PLoS Med. 2021 Jun 1;18(6):e1003631. doi: 10.1371/journal.pmed.1003631. eCollection 2021 Jun.

引用本文的文献

2
Labeled NSAID hypersensitivity and the risk of opioid prescribing; an observational study.
Front Allergy. 2025 Jul 29;6:1611309. doi: 10.3389/falgy.2025.1611309. eCollection 2025.
3
Sex differences in comorbid pain and opioid use disorder: A scoping review.
Br J Clin Pharmacol. 2024 Dec;90(12):3067-3083. doi: 10.1111/bcp.16218. Epub 2024 Aug 21.
4
[Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs (2024, Chengdu)].
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Jun;38(6):453-462. doi: 10.13201/j.issn.2096-7993.2024.06.001.
5
How to Define and Manage Low-Risk Drug Allergy Labels.
J Allergy Clin Immunol Pract. 2024 May;12(5):1095-1106. doi: 10.1016/j.jaip.2024.03.021.
6
Consequences of NSAID allergy on pain control options for patients with aspirin-exacerbated respiratory disease.
J Allergy Clin Immunol Pract. 2024 Jun;12(6):1644-1646.e2. doi: 10.1016/j.jaip.2024.02.025. Epub 2024 Feb 28.
7
Nonsteroidal anti-inflammatory drug "allergy" labeling is associated with increased postpartum opioid utilization.
J Allergy Clin Immunol. 2024 Mar;153(3):772-779.e4. doi: 10.1016/j.jaci.2023.11.025. Epub 2023 Nov 30.
8
Neuroimmune Mechanisms of Opioid Use Disorder and Recovery: Translatability to Human Studies, and Future Research Directions.
Neuroscience. 2023 Sep 15;528:102-116. doi: 10.1016/j.neuroscience.2023.07.031. Epub 2023 Aug 9.
9
Association of Reported Nonsteroidal Anti-Inflammatory Drug (NSAID) Adverse Drug Reactions With Opioid Prescribing After Total Joint Arthroplasty.
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1891-1898.e3. doi: 10.1016/j.jaip.2023.03.017. Epub 2023 Mar 21.
10
Recent Updates in Understanding NSAID Hypersensitivity.
Curr Allergy Asthma Rep. 2023 Mar;23(3):181-188. doi: 10.1007/s11882-023-01064-3. Epub 2023 Feb 9.

本文引用的文献

1
Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018.
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297. doi: 10.15585/mmwr.mm6911a4.
2
Prevalence of respiratory conditions among people who use illicit opioids: a systematic review.
Addiction. 2020 May;115(5):832-849. doi: 10.1111/add.14870. Epub 2020 Jan 13.
3
Risk Factors for Misuse of Prescribed Opioids: A Systematic Review and Meta-Analysis.
Ann Emerg Med. 2019 Nov;74(5):634-646. doi: 10.1016/j.annemergmed.2019.04.019. Epub 2019 Jun 20.
4
Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity.
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2891-2893.e4. doi: 10.1016/j.jaip.2019.04.042. Epub 2019 May 14.
5
The challenge of de-labeling penicillin allergy.
Allergy. 2020 Feb;75(2):273-288. doi: 10.1111/all.13848. Epub 2019 May 26.
6
Prevention and Treatment of Opioid Misuse and Addiction: A Review.
JAMA Psychiatry. 2019 Feb 1;76(2):208-216. doi: 10.1001/jamapsychiatry.2018.3126.
7
9
Opioid Use Disorders: Perioperative Management of a Special Population.
Anesth Analg. 2018 Aug;127(2):539-547. doi: 10.1213/ANE.0000000000003477.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验